BrightSpring Health Services, Inc. (BTSG)

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$60.11-1.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge BrightSpring Health Services, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.4%

+10% or more+5%0%−5%−10% or less

2.31 → 2.32 EPS · FY ending Dec 31, 2027 · 10 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 10 to 10; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	4.01B
EPS	—	0.513
FY 2026 · Annual
Revenue	—	15.37B
EPS	—	1.824
EBITDA	$820M–$845Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	17.44B
EPS	—	2.315

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross profit grows to at least $482M quarterly	A supporting condition in BrightSpring Health Services, Inc.'s published investment case. The stated target is >= $482M per quarter.	Intact	Gross profit falls below $338M quarterly	Gross profit: $492.746M FY2026-Q2; GAAP. Published target: >= $482M per quarter. Target period is not explicitly aligned with this observation. Source published Jul 31, 2026492,746,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e9f6907e-9262-4e04-b6cf-98fa02a67c0f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves to at least $121M quarterly	Profit margins improve with operating income rising from $50.7M to $121.4M in one year.	Intact	Operating income falls below $50M quarterly	Operating income: $130.391M FY2026-Q2; GAAP. Published target: >= $121M per quarter. Target period is not explicitly aligned with this observation. Source published Jul 31, 2026130,391,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e9f6907e-9262-4e04-b6cf-98fa02a67c0f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Adjusted EBITDA grew from $131M in 2025-Q1 to $206M in 2026-Q2, a 57% increase. Full year 2026 guidance raised to $820M-$845M, reflecting 32.8%-36.8% growth. Management is delivering sustained profitability improvements consistent with stated goals. Delivery assessment Oct 24, 2026
Revenue grows to about $14.9B in FY26	BrightSpring Health Services grows revenue about 16% yearly, backed by raised guidance to nearly $15B in 2026.	Intact	Revenue falls below $12.5B in FY26	Revenue: $3.873B FY2026-Q2; GAAP. Published target: ~$14.875B. Target period is not explicitly aligned with this observation. Source published Jul 31, 20263,873,140,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e9f6907e-9262-4e04-b6cf-98fa02a67c0f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Revenue grew from $2.878B in 2025-Q1 to $3.873B in 2026-Q2. Full year 2026 Revenue guidance increased to $15.1B-$15.425B, representing 17.0% to 19.5% growth over 2025. Management is delivering consistent revenue growth aligned with stated priorities. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.32

$2.14 → $2.32 · observed estimates

FY2027 revenue$17.44B

$17.12B → $17.44B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.14	$17,116,877,420	17 / 19
2026-07-25	$2.13	$17,108,985,240	16 / 18
2026-07-26	$2.13	$17,108,985,240	16 / 18
2026-07-27	$2.13	$17,108,985,240	16 / 18
2026-07-28	$2.13	$17,108,985,240	16 / 18
2026-07-29	$2.13	$17,108,996,350	16 / 18
2026-07-30	$2.13	$17,108,996,350	16 / 18
2026-07-31	$2.13	$17,108,996,350	16 / 18
2026-08-01	$2.13	$17,108,996,350	16 / 18
2026-08-02	$2.13	$17,108,996,350	16 / 18
2026-08-03	$2.22	$17,245,778,550	15 / 17
2026-08-04	$2.22	$17,245,778,550	15 / 17
2026-08-05	$2.27	$17,398,357,890	16 / 18
2026-08-06	$2.27	$17,398,357,890	16 / 18
2026-08-07	$2.28	$17,366,487,389	9 / 13
2026-08-08	$2.28	$17,366,487,389	9 / 13
2026-08-09	$2.28	$17,415,891,890	17 / 18
2026-08-10	$2.28	$17,366,487,389	9 / 13
2026-08-11	$2.28	$17,415,891,890	17 / 18
2026-08-12	$2.28	$17,415,891,890	17 / 18
2026-08-13	$2.28	$17,366,487,389	9 / 13
2026-08-14	$2.28	$17,366,487,389	9 / 13
2026-08-15	$2.28	$17,366,487,389	10 / 13
2026-08-16	$2.28	$17,366,487,389	10 / 13
2026-08-17	$2.28	$17,366,487,389	10 / 13
2026-08-18	$2.28	$17,366,487,389	10 / 13
2026-08-19	$2.28	$17,366,487,389	10 / 13
2026-08-20	$2.31	$17,415,891,889	10 / 14
2026-08-21	$2.31	$17,415,891,889	10 / 14
2026-08-22	$2.31	$17,415,891,889	10 / 14
2026-08-23	$2.31	$17,415,891,889	10 / 14
2026-08-24	$2.31	$17,415,891,889	10 / 14
2026-08-25	$2.31	$17,415,891,889	10 / 14
2026-08-26	$2.31	$17,415,891,889	10 / 14
2026-08-27	$2.31	$17,415,891,889	10 / 14
2026-08-28	$2.31	$17,415,891,889	10 / 14
2026-08-29	$2.31	$17,424,054,582	10 / 14
2026-08-30	$2.31	$17,424,054,582	10 / 14
2026-08-31	$2.31	$17,424,054,582	10 / 14
2026-09-01	$2.31	$17,424,054,582	10 / 14
2026-09-02	$2.31	$17,424,054,582	10 / 14
2026-09-03	$2.31	$17,424,054,582	10 / 14
2026-09-04	$2.31	$17,424,054,582	10 / 14
2026-09-05	$2.31	$17,424,054,582	10 / 14
2026-09-06	$2.31	$17,424,054,582	10 / 14
2026-09-07	$2.31	$17,424,054,582	10 / 14
2026-09-08	$2.31	$17,424,054,582	10 / 14
2026-09-09	$2.31	$17,424,054,582	10 / 14
2026-09-10	$2.31	$17,424,054,582	10 / 14
2026-09-11	$2.31	$17,424,054,582	10 / 14
2026-09-12	$2.31	$17,424,054,582	10 / 14
2026-09-13	$2.31	$17,424,054,582	10 / 14
2026-09-14	$2.31	$17,424,054,582	10 / 14
2026-09-15	$2.31	$17,424,054,582	10 / 14
2026-09-16	$2.31	$17,424,054,582	10 / 14
2026-09-17	$2.31	$17,424,054,582	10 / 14
2026-09-18	$2.31	$17,424,054,582	10 / 14
2026-09-19	$2.31	$17,424,054,582	10 / 14
2026-09-20	$2.31	$17,424,054,582	10 / 14
2026-09-21	$2.31	$17,424,054,582	10 / 14
2026-09-22	$2.31	$17,424,054,582	10 / 14
2026-09-23	$2.31	$17,424,054,582	10 / 14
2026-09-24	$2.31	$17,424,054,582	10 / 14
2026-09-25	$2.31	$17,424,054,582	10 / 14
2026-09-26	$2.31	$17,424,054,582	10 / 14
2026-09-27	$2.31	$17,424,054,582	10 / 14
2026-09-28	$2.31	$17,424,054,582	10 / 14
2026-09-29	$2.31	$17,424,054,582	10 / 14
2026-09-30	$2.31	$17,424,054,582	10 / 14
2026-10-01	$2.31	$17,424,155,526	10 / 14
2026-10-02	$2.31	$17,424,155,526	10 / 14
2026-10-03	$2.31	$17,424,155,526	10 / 14
2026-10-04	$2.31	$17,424,155,526	10 / 14
2026-10-05	$2.31	$17,424,155,526	10 / 14
2026-10-06	$2.31	$17,424,155,526	10 / 14
2026-10-07	$2.31	$17,424,155,526	10 / 14
2026-10-08	$2.31	$17,424,155,526	10 / 14
2026-10-09	$2.31	$17,424,155,526	10 / 14
2026-10-10	$2.31	$17,424,155,526	10 / 14
2026-10-11	$2.31	$17,424,155,526	10 / 14
2026-10-12	$2.31	$17,424,155,526	10 / 14
2026-10-13	$2.31	$17,425,035,861	10 / 14
2026-10-14	$2.31	$17,425,035,861	10 / 14
2026-10-15	$2.31	$17,425,035,861	10 / 14
2026-10-16	$2.31	$17,425,035,861	10 / 14
2026-10-17	$2.31	$17,425,035,861	10 / 14
2026-10-18	$2.31	$17,425,035,861	10 / 14
2026-10-19	$2.32	$17,444,890,912	10 / 14
2026-10-20	$2.32	$17,444,890,912	10 / 14
2026-10-21	$2.32	$17,444,890,912	10 / 14
2026-10-22	$2.32	$17,444,890,912	10 / 14
2026-10-23	$2.32	$17,444,890,912	10 / 14
2026-10-24	$2.32	$17,444,890,912	10 / 14

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	16	0	0
2026-06-01	17	0	0
2026-07-01	19	0	0
2026-08-01	18	0	0
2026-09-01	18	0	0
2026-10-01	18	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 18 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross profit grows to at least $482M quarterlyGross profit: $492.746M
Operating income improves to at least $121M quarterlyOperating income: $130.391M
Revenue grows to about $14.9B in FY26Revenue: $3.873B

Next proof point

Oct 30, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-23.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BrightSpring Health Services, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

BTSG is a growth-oriented healthcare business with improving profitability, rather than a turnaround story. Its long-term thesis is intact, supported by recent results and management execution, but the evidence carries medium confidence and risk is elevated.

What's priced into BrightSpring Health Services, Inc.

Valuation is expensive versus peers, with a reported premium of 1.81. The expectations gap is modest at 0.08, and the evidence labels expectations as justified, with no fragility gates triggered; however, model confidence is low.

What the fundamentals likely do

Near-term results show strong revenue and adjusted EBITDA growth, and management raised its 2026 guidance after a July earnings beat. Patient reach and pharmacy service use are also expanding, while the near-term miss risk is described as low despite a history of a deep miss and recent peer misses. A weakening jobs trend is a risk because recession concerns can weigh more heavily on cyclical businesses.

What BrightSpring Health Services, Inc. hinges on

The thesis depends on management sustaining growth and profitability after raising guidance; reversing course with a guidance cut would also damage credibility. Healthcare sector momentum could support the setup if bellwethers continue to beat results and raise guidance, while a further weakening in jobs data could increase recession concerns.